Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Armodafinil extension in bipolar I depression
NCT01121536Phase 3Terminated
- Sponsor
- Cephalon, Inc.
- Start
- Apr 2010
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, open-label, single-arm trial of armodafinil in bipolar I disorder, sponsored by Cephalon, Inc. Primary endpoints: Treatment-Emergent Adverse Events at 6 months, Clinically Significant Abnormal Serum Chemistry Values at 6 months and 10 more. Started Apr 2010; status: terminated.
02
Drugs
armodafinil
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT01121536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01121536.